Anti-tuberculosis treatment strategies and drug development: challenges and priorities
VA Dartois, EJ Rubin - Nature Reviews Microbiology, 2022 - nature.com
Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …
biological uncertainties remain and hamper progress. However, owing to collaborative …
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs …
to estimate the association of treatment success and death with the use of individual drugs …
Treatment of highly drug-resistant pulmonary tuberculosis
Background Patients with highly drug-resistant forms of tuberculosis have limited treatment
options and historically have had poor outcomes. Methods In an open-label, single-group …
options and historically have had poor outcomes. Methods In an open-label, single-group …
Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline
Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America …
Prevention, European Respiratory Society, and Infectious Diseases Society of America …
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …
tuberculosis remains out of control in several parts of the world including Africa and Asia …
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …
combination of multiple second-line drugs. These drugs are associated with numerous …
Advances in the development of new tuberculosis drugs and treatment regimens
Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …
[HTML][HTML] New agents for the treatment of drug-resistant Mycobacterium tuberculosis
DT Hoagland, J Liu, RB Lee, RE Lee - Advanced drug delivery reviews, 2016 - Elsevier
Inadequate dosing and incomplete treatment regimens, coupled with the ability of the
tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have …
tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have …
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid …
Background Improved genetic understanding of Mycobacterium tuberculosis (MTB)
resistance to novel and repurposed anti-tubercular agents can aid the development of rapid …
resistance to novel and repurposed anti-tubercular agents can aid the development of rapid …
[책][B] WHO operational handbook on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment
World Health Organization - 2020 - apps.who.int
The World Health Organization (WHO) has produced this WHO operational handbook on
tuberculosis to provide practical advice to complement the latest WHO consolidated …
tuberculosis to provide practical advice to complement the latest WHO consolidated …